Insulin vs MOTS-c
Overview
Insulin and MOTS-c are both weight management & metabolic peptides, but they differ in mechanism, dosing, and regulatory status.
This page compares Insulin and MOTS-c across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Insulin | MOTS-c | |
|---|---|---|
| Category | Weight Management & Metabolic | Weight Management & Metabolic |
| Regulatory status (US) | FDA approved | Compounding (Rx) — Apr 2026 |
| Typical dosage | Highly individualized; type 1 diabetes basal-bolus regimens typically require 0.5–1.0 units/kg/day total; type 2 diabetes is often initiated with basal insulin at 10 units or 0.1–0.2 units/kg/day, titrated to individual glycemic targets | 5-10 mg |
| Frequency | Once daily (long-acting basal analogs) to four or more times daily (basal-bolus or continuous subcutaneous insulin infusion); prandial doses given 0–15 minutes before meals for rapid-acting analogs or 30 minutes before meals for regular human insulin | weekly |
| Reported benefits | Glycemic control, prevention of diabetic ketoacidosis, reduction of microvascular complications (retinopathy, nephropathy, neuropathy), life-sustaining therapy in type 1 diabetes, HbA1c reduction in type 2 diabetes | Enhanced metabolism, improved insulin sensitivity, increased exercise capacity, longevity benefits |
| Reported side effects | Hypoglycemia, weight gain, injection-site lipohypertrophy, rare hypersensitivity reactions, peripheral edema at initiation | Well-tolerated. Minimal reported side effects |
Key differences
Primary use. Insulin is categorised under Weight Management & Metabolic, while MOTS-c falls under Weight Management & Metabolic. Because they target a similar goal, they are common alternatives to weigh against each other.
Regulatory status. Insulin: FDA-approved. MOTS-c: not FDA-approved; compounding permitted with a prescription as of April 2026.
Dosing. Insulin is typically dosed at Highly individualized; type 1 diabetes basal-bolus regimens typically require 0.5–1.0 units/kg/day total; type 2 diabetes is often initiated with basal insulin at 10 units or 0.1–0.2 units/kg/day, titrated to individual glycemic targets (Once daily (long-acting basal analogs) to four or more times daily (basal-bolus or continuous subcutaneous insulin infusion); prandial doses given 0–15 minutes before meals for rapid-acting analogs or 30 minutes before meals for regular human insulin). MOTS-c is typically dosed at 5-10 mg (weekly).
Can you stack them?
Some protocols combine peptides, but stacking Insulin and MOTS-c has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Insulin and MOTS-c?
- Insulin and MOTS-c are both weight management & metabolic peptides, but they differ in mechanism, dosing, and regulatory status. Insulin is FDA-approved for one or more indications, whereas MOTS-c is not FDA-approved; compounding permitted with a prescription (as of April 2026).
- What is Insulin used for?
- The foundational peptide hormone for glycemic management in type 1 and type 2 diabetes mellitus.
- What is MOTS-c used for?
- Mitochondrial optimization.
- Can you take Insulin and MOTS-c together?
- Some users combine peptides within a single protocol, but stacking Insulin and MOTS-c has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Insulin or MOTS-c FDA-approved?
- Insulin is FDA-approved for one or more indications. MOTS-c is not FDA-approved; compounding permitted with a prescription (as of April 2026).